National Bank of Canada
CBIO

National Bank of Canada’s Crescent Biopharma CBIO Stock Holding History

National Bank of Canada’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6
Closed -$177 – 2874
2024
Q2 		$177 Buy
+6
New +$624 ﹤0.01% 2610

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

National Bank of Canada's CBIO Position: Q3 2024 in Review

National Bank of Canada sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 6 shares — an estimated $177 sold.

National Bank of Canada first reported a position in CBIO in Q2 2024 and held it in 1 quarter. The position peaked at $177 in Q2 2024. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

  • National Bank of Canada reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
  • National Bank of Canada sold 6 Crescent Biopharma shares in Q3 2024, an estimated $177.
  • National Bank of Canada first reported a position in Crescent Biopharma in Q2 2024 and held it in 1 quarter.
  • National Bank of Canada's Crescent Biopharma position peaked at $177 in Q2 2024.
  • 36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.